



November 5, 2012

ImmunoCellular Therapeutics to Present at Lazard Capital Markets 9th Annual Healthcare Conference on November 14th

Los Angeles, CA – November 5, 2012 – ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that John S. Yu, MD, Interim Chief Executive Officer, will present a corporate overview and business update at the Lazard Capital Markets 9th Annual Healthcare Conference on November 14, 2012 at 11:00 am ET at the Pierre Hotel in New York City.

To access the live audio webcast of the Lazard presentation, please log on through a link located in the Investor Relations section of ImmunoCellular's website at www.imuc.com, under the Investors, Webcasts & Presentations tab. A replay of the webcasts will be available one hour after the conclusion of the live event.

In addition, Peter Ho, PhD, Director of Business Development, will present a company overview on November 14, 2012 at the 18th annual BIO-Europe® international partnering conference on November 14, 2012 at 9:30 GMT at the CCH Congress Center, Hamburg, Germany.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. To learn more about ImmunoCellular, please visit www.imuc.com.

Contact Information:

ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
Tel: (415) 347-0010
Email: jane@jmgcomm.com

Source: ImmunoCellular Therapeutics, Ltd.